You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Two recent CRISPR-Cas9 viability screens in cancer cell lines were concordant across multiple metrics despite significant differences in experimental protocols.
Promega said it plans to use the technology to create new research products for investigating endogenous biology.
An editorial in the South China Morning Post seeks to learn from the He Jiankui gene-editing affair.
The companies will identify and optimize novel CRISPR proteins owned by Mammoth, and then license those proteins to Horizon for use in engineered cell lines.
Gene editing could be an issue competitive sports need to address soon, four researchers from Arizona State University write at Slate.
In Nature this week: genetic "clock" that can predict the lifespans of vertebrates, new assembler called wtdbg2, and more.
Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.
The company said it will use the funds to accelerate the development of applications for its Onyx Digital Genome Engineering platform.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.